Circulating Biologically Active Adrenomedullin (bio-ADM) Predicts Hemodynamic Support Requirement and Mortality During Sepsis

Circulating Biologically Active Adrenomedullin (bio-ADM) Predicts Hemodynamic Support Requirement and Mortality During Sepsis
复制标题

DOI:
10.1016/j.chest.2017.03.035
复制
发表时间:
2017-08-01
期刊:
影响因子:
9.6
通讯作者:
Masson, Serge
Masson, Serge
中科院分区:
医学1区
文献类型:
--
作者:
Caironi, Pietro;Latini, Roberto;Masson, Serge

文献摘要

被引文献

相似文献

背景技术背景:肾上腺髓质素(ADM)是一种参与血液动力学稳态的激素,其生物学作用在脓毒症中存在争议,因为给予肽或针对它的抗体可能是有益的。在第1,2,在多中心白蛋白研究中,956例脓毒症或脓毒性休克患者随机接受白蛋白或晶体液进行液体复苏后,意大利脓毒症结局试验。我们检测了bio-ADM及其时间依赖性变化与液体治疗、血管加压药给药、器官衰竭和死亡率的关系。第1天血浆bio-ADM(中位数[Q1-Q3],110 [59-198] pg/mL)在脓毒性休克患者中较高,与90天死亡率、多器官衰竭和血流动力学支持治疗的平均程度相关(液体和血管加压剂)和第一周的血清乳酸时间过程。此外,它还可预测入组时无休克的患者发生心血管功能障碍(OR [95%CI],1.9 [1.4-2.5]; P
BACKGROUND: The biological role of adrenomedullin (ADM), a hormone involved in hemodynamic homeostasis, is controversial in sepsis because administration of either the peptide or an antibody against it may be beneficial.METHODS: Plasma biologically active ADM (bio-ADM) was assessed on days 1, 2, and 7 after randomization of 956 patients with sepsis or septic shock to albumin or crystalloids for fluid resuscitation in the multicenter Albumin Italian Outcome Sepsis trial. We tested the association of bio-ADM and its time-dependent variation with fluid therapy, vasopressor administration, organ failures, and mortality.RESULTS: Plasma bio-ADM on day 1 (median [Q1-Q3], 110 [59-198] pg/mL) was higher in patients with septic shock, associated with 90-day mortality, multiple organ failures and the average extent of hemodynamic support therapy (fluids and vasopressors), and serum lactate time course over the first week. Moreover, it predicted incident cardiovascular dysfunction in patients without shock at enrollment (OR [95% CI], 1.9 [1.4-2.5]; P